Mannkind Corpor Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mannkind Corpor (US): 4 reconciled FDA prescription therapies, $57.9M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$57.9M
2024 Medicare Part D Spend$48.7M
2024 Medicaid Spend$9.2M
California HCAI SB 17 Filings12 WAC filings (max 19.1% 2-yr change)